Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers

Published:November 08, 2019DOI:


      Migraine headaches are among the most common and potentially debilitating disorders encountered by primary healthcare providers. In the treatment of acute migraine and the prevention of recurrent attacks, there are prescription drugs of proven benefit. However, for those without health insurance or high co-pays, these drugs may be neither available nor affordable and, for all patients, they may be either poorly tolerated or contraindicated.
      The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1300 mg, taken at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including some, but not all, randomized trials, suggests the possibility that daily aspirin, in doses from 81 to 325 mg, may be an effective and safe treatment option for the prevention of recurrent migraine headaches.
      The relatively favorable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers in the treatment of both acute and recurrent migraine headaches.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Burch R
        • Rizzoli P
        • Loder E
        The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies.
        Headache. 2018; 58: 496-505
        • Kingston WS
        • Halker Singh RB
        Determinants of suboptimal migraine diagnosis and treatment in the primary care setting.
        J Clin Outcomes Manage. 2017; 24: 319-324
        • Lipton RB
        • Bigal ME
        • Diamond M
        • et al.
        Migraine prevalence, disease burden, and the need for preventive therapy.
        Neurology. 2007; 68: 343-349
      1. The international classification of headache disorders, 3rd edition (beta version).
        Cephalalgia. 2013; 33: 629-808
        • Diener HC
        • Solbach K
        • Holle D
        • Gaul C
        Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options.
        Clin Med (Lond). 2015; 15: 344-350
        • The American Headache Society
        The American Headache Society position statement on integrating new migraine treatments into clinical practice.
        Headache. 2019; 59: 1-18
        • Lange R
        • Schwarz JA
        • Hohn M
        Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomised, double-blind, single-dose, placebo-controlled parallel group study.
        Cephalalgia. 2000; 20: 663-667
        • Diener HC
        • Bussone G
        • de Liano H
        • et al.
        Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks.
        Cephalalgia. 2004; 24: 947-954
        • Diener HC
        • Eikermann A
        • Gessner U
        • et al.
        Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms.
        Eur Neurol. 2004; 52: 50-56
        • Jaspers Focks J
        • Tielemans MM
        • van Rossum LG
        • et al.
        Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin.
        Neth Heart J. 2014; 22: 107-112
      2. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.
        Eur Neurol. 1992; 32: 177-184
        • Kirthi V
        • Derry S
        • Moore RA
        Aspirin with or without an antiemetic for acute migraine headaches in adults.
        Cochrane Database Syst Rev. 2013; CD008041
      3. Food and Drug Administration. FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs [press release]. Available at: Accessed October 8, 2019.

        • Hennekens CH
        • Borzak S
        • Bjorkman DJ
        Cardiovascular risks of non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: necessary but not sufficient for clinical decision making.
        Expert Rev Cardiovasc Ther. 2014; 12: 291-293
        • Nappi G
        • Sandrini G
        • Sances G
        Tolerability of the triptans: clinical implications.
        Drug Saf. 2003; 26: 93-107
        • Diener HC
        • Hartung E
        • Chrubasik J
        • et al.
        A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study.
        Cephalalgia. 2001; 21: 120-128
        • Linde M
        • Mulleners WM
        • Chronicle EP
        • McCrory DC
        Topiramate for the prophylaxis of episodic migraine in adults.
        Cochrane Database Syst Rev. 2013; CD010610
        • Herd CP
        • Tomlinson CL
        • Rick C
        • et al.
        Botulinum toxins for the prevention of migraine in adults.
        Cochrane Database Syst Rev. 2018; 6CD011616
        • Dyer O
        US approves first monoclonal antibody to prevent migraines.
        BMJ. 2018; 361: k2228
        • Castle D
        • Robertson NP
        Monoclonal antibodies for migraine: an update.
        J Neurol. 2018; : 1491-1492
        • Steering Committee of the Physicians’ Health Study Research Group.
        Preliminary report: findings from the aspirin component of the ongoing Physicians’ Health Study.
        N Engl J Med. 1988; 318: 262-264
        • The Steering Committee of the Physicians’ Health Study Research Group.
        Final report on the aspirin component of the ongoing Physicians’ Health Study.
        N Engl J Med. 1989; 321: 129-135
        • Peto R
        • Gray R
        • Collins R
        • et al
        A randomised trial of of prophylactic daily aspirin in British male doctors.
        Br Med J (Clin Res Ed). 1988; 296: 313-316
        • Buring JE
        • Peto R
        • Hennekens CH
        Low-dose aspirin for migraine prophylaxis.
        JAMA. 1990; 264: 1711-1713.
        • Ridker PM
        • Cook NR
        • Lee IM
        • et al.
        A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
        N Engl J Med. 2005; 352: 1293-1304
        • Schürks M
        • Rist PM
        • Bigal ME
        • Buring JE
        • Lipton RB
        • Kurth T
        Migraine and cardiovascular disease: systematic review and meta-analysis.
        BMJ. 2009; 339: b3914
        • Buring JE
        • Hebert P
        • Romero J
        • et al.
        Migraine and subsequent risk of stroke in the Physicians’ Health Study.
        Arch Neurol. 1995; 52: 129-134
        • Benseñor IM
        • Cook NR
        • Lee I-M
        • Chown MJ
        • Hennekens CH
        • Buring JE
        Low-dose aspirin for migraine prophlaxis in women.
        Cephalalgia. 2001; 21: 175-183
        • Baena CP
        • D'Amico RC
        • Slongo H
        • Brunoni AR
        • Goulart AC
        • Benseñor I
        The effectiveness of aspirin for migraine prophylaxis: a systematic review.
        Sao Paulo Med J. 2017; 135: 42-49

      Linked Article